Advocacy intelligence hub — real-time data for patient organizations
Trogarzo: FDA approved
TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Trogarzo
(ibalizumab)Orphan drugTheratechnologies Inc.
CD4-directed Blocking Antibody [EPC]
12.1 Mechanism of Action Ibalizumab-uiyk is an HIV-1 antiretroviral drug [see Microbiology ( 12.4 )] .
Browse all Acute disseminated encephalomyelitis without anti-MOG antibodies news →
View all Acute disseminated encephalomyelitis without anti-MOG antibodies specialists →